Ketamine treatment for refractory anxiety: A systematic review.
Br J Clin Pharmacol
; 88(10): 4412-4426, 2022 10.
Article
en En
| MEDLINE
| ID: mdl-35510346
ABSTRACT
There is a growing interest in the psychiatric properties of the dissociative anaesthetic ketamine, as single doses have been shown to have fast-acting mood-enhancing and anxiolytic effects, which persist for up to a week after the main psychoactive symptoms have diminished. Therefore, ketamine poses potential beneficial effects in patients with refractory anxiety disorders, where other conventional anxiolytics have been ineffective. Ketamine is a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, which underlies its induction of pain relief and anaesthesia. However, the role of NMDA receptors in anxiety reduction is still relatively unknown. To fill this paucity in the literature, this systematic review assesses the evidence that ketamine significantly reduces refractory anxiety and discusses to what extent this may be mediated by NMDA receptor antagonism and other receptors. We highlight the temporary nature of the anxiolytic effects and discuss the high discrepancy among the study designs regarding many fundamental factors such as administration routes, complementary treatments and other treatments.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Ansiolíticos
/
Ketamina
Tipo de estudio:
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Br J Clin Pharmacol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Reino Unido